SecBot SecBot
DEF 14A ·Filed Oct 26, 2026

TCRX

TScan Therapeutics, Inc.
BEARISH
Impact 6/10
Processed1h 44m ago SEC0001193125-26-431045
Definitive proxy statement

Price Chart

Loading chart...

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEF 14A Filing (Primary)0001193125-26-431045
Document: 0001193125-26-431045-index-headers.html0001193125-26-431045
Document: 0001193125-26-431045-index.html0001193125-26-431045
Document: 0001193125-26-431045.txt0001193125-26-431045
14 reports for TCRX
Performance horizon
86% Hit rate @ T+20 6 of 7 directional calls Went positive at some point 7 of 7 best @ T+20▲ +58.87%Aug 12, 2026
Filters
Rows
Reports for TCRX — sortable, filterable
TypeNow
Oct 26, 2026
today
DEF 14A
BEARISH ★ 6/10
—awaiting T+20——
Oct 16, 2026
9d ago
8-K
NEUTRAL ★ 2/10
$0.2102awaiting T+20—$0.1965 (−6.52%)
Sep 30, 2026
25d ago
8-K
NEUTRAL ★ 2/10
$0.3175awaiting T+20—$0.1965 (−38.11%)
Sep 25, 2026
4w ago
SC 13G
NEUTRAL ★ 3/10
$0.3400awaiting T+20—$0.1965 (−42.21%)
Sep 11, 2026
6w ago
8-K
NEUTRAL ★ 5/10
$0.3204 $0.2380▼ −25.72%▼ −27.59%$0.1965 (−38.67%)
Sep 2, 2026
7w ago
8-K
BEARISH ★ 7/10
$0.3810 $0.3150▲ +17.32%▲ +17.24%$0.1965 (+48.43%)
Aug 18, 2026
9w ago
8-K
BEARISH ★ 7/10
$0.7500 $0.3335▲ +55.53%▲ +53.58%$0.1965 (+73.80%)
Aug 12, 2026
10w ago
8-K
BEARISH ★ 6/10
$0.7730 $0.3179▲ +58.87%▲ +56.98%$0.1965 (+74.58%)
Aug 12, 2026
10w ago
Press Release
BEARISH ★ 6/10
$0.7730 $0.3179▲ +58.87%▲ +56.98%$0.1965 (+74.58%)
Jun 22, 2026
18w ago
8-K
BULLISH ★ 6/10
$0.8651 $0.9148▲ +5.75%▲ +5.89%$0.1965 (−77.29%)
Showing 10 of 14

US Market Status

Market Open — Closes in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh TCRX Intelligence

Analysis is for subscribers only.

TScan Therapeutics is holding a special meeting on November 20, 2026, to seek stockholder approval for a reverse stock split (ratio between 1:2 and 1:50) to regain compliance with Nasdaq's $1.00 minimum bid price requirement after receiving a deficiency notice on August 27, 2026. The stock closed…

Subscribe for Full Access